Gene-drug interactions (data source: DGIdb)
Gene Name Entrez ID Drug Name Chembl ID Interaction Types Sources publications
CHRNA5 1138 MAPROTILINE CHEMBL21731 antagonist GuideToPharmacologyInteractions
CHRNA5 1138 POZANICLINE CHEMBL127071 partial agonist ChemblInteractions

Variant-drug associations (data source: PharmGKB)
Gene Name Variant Alleles Chemical Phenotype Category Significance Notes Sentence Publications Annotation ID
CHRNA5 rs67624739 del bupropion efficacy no Authors looked at the effect of variants on response to the smoking cessation therapies varenicline, bupropion and nicotine replacement therapy. Variant is reported as rs3841324 in the paper and also given the alias rs67624739. Allele del is not associated with response to bupropion, nicotine and varenicline in people with Tobacco Use Disorder as compared to allele CAGAGGGAAATAGGGGCGGGGC. 29196725 1451159800
CHRNA5 rs588765 C nicotine dosage no Allele C is not associated with dose of nicotine in people with Tobacco Use Disorder as compared to allele T. 26010901 1444930299
CHRNA5 rs615470 T nicotine other no No significant association between this allele and status as a smoker or non-smoker. Allele T is not associated with exposure to nicotine in men as compared to allele C. 29666375 1450930674
CHRNA5 rs2036527 AA + AG bupropion efficacy yes Women with the AA or AG genotypes were more likely to be abstinent from smoking at 6 months after starting pharmacotherapy for smoking cessation compared to those with the GG genotype. Genotypes AA + AG are associated with increased response to bupropion, nicotine or varenicline in women with Tobacco Use Disorder as compared to genotype GG. 29621993 1450928764
CHRNA5 rs2036527 A bupropion efficacy no No significant effect of genotype on likelihood of male subjects being abstinent from smoking at 6 months after starting pharmacotherapy for smoking cessation. Allele A is not associated with response to bupropion, nicotine or varenicline in men with Tobacco Use Disorder as compared to allele G. 29621993 1450928783
CHRNA5 rs680244 C Drugs used in nicotine dependence other yes in haplotype analysis; individuals with haplotype 3 (rs16969968 allele A - rs680244 allele C) were more likely to respond to active treatment/ had a lower risk of relapse (ability to quit smoking as measured by time to relapse to smoking over 60 days) than those with haplotype 3 that were treated with placebo. The ability to quit cigarette smoking were not significantly different in individuals with haplotype 1 (rs16969968 allele G - rs680244 allele C) that underwent active treatment compared to placebo (p=0.36). Allele C is associated with increased response to Drugs used in nicotine dependence in people with Tobacco Use Disorder. 22648373 827921983
CHRNA5 rs514743 T nicotine other no No significant association between this allele and status as a smoker or non-smoker. Allele T is not associated with exposure to nicotine in men as compared to allele A. 29666375 1450930662
CHRNA5 rs16969968 GG nicotine other yes Genotype GG is associated with decreased total puff volume when exposed to nicotine compared to cigarettes containing placebo in people with Tobacco Use Disorder as compared to genotypes AA + AG. Genotype GG is associated with decreased dose of nicotine in people with Tobacco Use Disorder as compared to genotypes AA + AG. 23358500 1448107584
CHRNA5 rs16969968 GG nicotine efficacy no Response here refers to smoking cessation outcomes at 7 days and nicotine refers to nicotine patches. Smoking cessation outcomes at 6 months and 12 months were also not significantly associated with genotype. Genotype GG is not associated with response to nicotine or varenicline in people with Tobacco Use Disorder as compared to genotypes AA + AG. 26010901 1444930241
CHRNA5 rs16969968 AA + AG bupropion efficacy yes Women with the AA or AG genotypes were more likely to be abstinent from smoking at 6 months after starting pharmacotherapy for smoking cessation compared to those with the GG genotype. Genotypes AA + AG are associated with increased response to bupropion, nicotine or varenicline in women with Tobacco Use Disorder as compared to genotype GG. 29621993 1450928770
CHRNA5 rs16969968 A cotinine metabolism/PK yes The authors conducted a GWAS meta-analysis to identify genetic variants associated with cotinine in current daily smokers (Caucasian). The following study cohorts were analyzed: ALSPAC, CARDIA, FinnTwin, Framingham, GenMets, MESA, NESDA, NTR, TwinsUK, YFS. This SNP was re-analyzed because of previous evidence demonstrating association with smoking quantity. It was also significantly associated with cotinine levels in the meta-analysis. Allele A is associated with increased concentrations of cotinine in people with Tobacco Use Disorder as compared to allele G. 26833182 1447814223
CHRNA5 rs588765 C cotinine metabolism/PK no The authors conducted a GWAS meta-analysis to identify genetic variants associated with cotinine in current daily smokers (Caucasian). The following study cohorts were analyzed: ALSPAC, CARDIA, FinnTwin, Framingham, GenMets, MESA, NESDA, NTR, TwinsUK, YFS. Allele C is not associated with concentrations of cotinine in people with Tobacco Use Disorder as compared to allele T. 26833182 1447814235
CHRNA5 rs588765 TT nicotine efficacy no Response here refers to smoking cessation outcomes at 7 days and nicotine refers to nicotine patches. Smoking cessation outcomes at 6 months and 12 months were also not significantly associated with genotype. Genotype TT is not associated with response to nicotine or varenicline in people with Tobacco Use Disorder as compared to genotypes CC + CT. 26010901 1444930247
CHRNA5 rs680244 T Drugs used in nicotine dependence other yes in haplotype analysis; individuals with haplotype 2 (rs16969968 allele G - rs680244 allele T) were more likely to respond to active treatment/ had a lower risk of relapse (ability to quit smoking as measured by time to relapse to smoking over 60 days) than those with haplotype 2 that were treated with placebo. The ability to quit cigarette smoking was not significantly different in individuals with haplotype 1 (rs16969968 allele G - rs680244 allele C) that underwent active treatment compared to placebo (p=0.36). Allele T is associated with increased response to Drugs used in nicotine dependence in people with Tobacco Use Disorder. 22648373 827922003
CHRNA5 rs621849 G nicotine other no The G allele was initially associated with an increased likelihood of being a smoker but this lost significance following correction for multiple testing. Allele G is not associated with exposure to nicotine in men as compared to allele A. 29666375 1450930632
CHRNA5 rs6495306 G nicotine other no The G allele was initially associated with an increased likelihood of being a smoker but this lost significance following correction for multiple testing. Allele G is not associated with exposure to nicotine in men as compared to allele A. 29666375 1450930652
CHRNA5 rs503464 A bupropion efficacy yes Authors looked at the effect of variants on response to the smoking cessation therapies varenicline, bupropion and nicotine replacement therapy. Allele A is associated with increased response to bupropion, nicotine and varenicline in people with Tobacco Use Disorder as compared to allele T. 29196725 1449155990
CHRNA5 rs55853698 G bupropion efficacy no Authors looked at the effect of variants on response to the smoking cessation therapies varenicline, bupropion and nicotine replacement therapy. Allele G is not associated with response to bupropion, nicotine and varenicline in people with Tobacco Use Disorder as compared to allele T. 29196725 1449155997
CHRNA5 rs555018 G nicotine other no The G allele was initially associated with an increased likelihood of being a smoker but this lost significance following correction for multiple testing. Allele G is not associated with exposure to nicotine in men as compared to allele A. 29666375 1450930627
CHRNA5 rs588765 T nicotine other no The T allele was initially associated with an increased likelihood of being a smoker but this lost significance following correction for multiple testing. Allele T is not associated with exposure to nicotine in men as compared to allele C. 29666375 1450930647
CHRNA5 rs647041 T nicotine other no No significant association between this allele and status as a smoker or non-smoker. Allele T is not associated with exposure to nicotine in men as compared to allele C. 29666375 1450930669
CHRNA5 rs55781567 G bupropion efficacy no Authors looked at the effect of variants on response to the smoking cessation therapies varenicline, bupropion and nicotine replacement therapy. Please note that alleles have been complemented to the positive strand. Allele G is not associated with response to bupropion, nicotine and varenicline in people with Tobacco Use Disorder as compared to allele C. 29196725 1449156003
CHRNA5 rs680244 T nicotine other no The T allele was initially associated with an increased likelihood of being a smoker but this lost significance following correction for multiple testing. Allele T is not associated with exposure to nicotine in men as compared to allele C. 29666375 1450930637
CHRNA5 rs692780 C nicotine other no The G allele was initially associated with an increased likelihood of being a smoker but this lost significance following correction for multiple testing. Allele C is not associated with exposure to nicotine in men as compared to allele G. 29666375 1450930642
CHRNA5 rs667282 C nicotine other no The C allele was initially associated with an increased likelihood of being a smoker but this lost significance following correction for multiple testing. Allele C is not associated with exposure to nicotine in men as compared to allele T. 29666375 1450930622
CHRNA5 rs16969968 A nicotine other no The A allele was initially associated with an increased likelihood of being a smoker but this lost significance following correction for multiple testing. Allele A is not associated with exposure to nicotine in men as compared to allele G. 29666375 1450930657
CHRNA5 rs16969968 A nicotine dosage yes The A allele of rs16969968 was significantly associated with 10% higher cotinine levels, however it was not significantly with self-reported number of cigarettes per day (P = 0.30). Smokers carrying an ‘A’ allele of rs16969968 had significantly higher cotinine per cigarette (P = 0.002). Allele A is associated with increased dose of nicotine in people with Tobacco Use Disorder as compared to allele G. 26010901 1444930282
CHRNA5 rs16969968 A bupropion efficacy no No significant effect of genotype on likelihood of male subjects being abstinent from smoking at 6 months after starting pharmacotherapy for smoking cessation. Allele A is not associated with response to bupropion, nicotine or varenicline in men with Tobacco Use Disorder as compared to genotype GG. 29621993 1450928777